Mariela H.
- Country
- Bulgaria
- Department
- N/A
Research Overview
- Long-Term Safety and Efficacy Assessment of Nemolizumab (CD14152) in Moderate-to-Severe Atopic Dermatitis Patients
- Efficacy, Safety, and Tolerability of Zasocitinib in Moderate-to-Severe Plaque Psoriasis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Ruxolitinib Cream in Pediatric Patients Aged 6 to <12 Years with Nonsegmental Vitiligo: A Phase 3 Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 47 of 200 partner sites.
Specializations
Atopic Dermatitis
Mariela Hitova is involved in clinical research focused on atopic dermatitis, with attention to both adult and pediatric disease management. Her trial portfolio includes evaluation of JAK inhibitor and other targeted anti-inflammatory approaches aimed at improving long-term control of eczema and related skin barrier disease.
- Upadacitinib dose flexibility in moderate-to-severe atopic dermatitis
- Nemolizumab in atopic dermatitis
- Dermatitis atopic
Her work also reflects interest in sustained symptom control and treatment optimization in chronic inflammatory skin disease.
Vitiligo
Her clinical research includes nonsegmental vitiligo, with studies spanning both adult and pediatric populations. The therapeutic focus centers on repigmentation strategies and the safety of targeted topical and systemic treatments for pigmentary disorders.
- Ritlecitinib in nonsegmental vitiligo
- Ruxolitinib cream in pediatric vitiligo
- Nonsegmental vitiligo
Her involvement highlights an interest in expanding therapeutic options for patients with visible, chronic depigmenting disease.
Hidradenitis Suppurativa
Mariela Hitova is active in research on hidradenitis suppurativa, a chronic inflammatory disorder with substantial impact on skin and quality of life. Her clinical interest in this area is directed toward maintaining response and preventing relapse in patients requiring ongoing disease control.
- Secukinumab in hidradenitis suppurativa
- Moderate-to-severe hidradenitis suppurativa
This area of work links her to biologic-based treatment strategies for difficult-to-manage suppurative skin disease.
Plaque Psoriasis
Her trial involvement extends to moderate-to-severe plaque psoriasis, with emphasis on targeted immune modulation for chronic plaque disease. The research focus includes evaluation of oral therapies designed to improve skin clearance and disease durability.
- TAK-279 in plaque psoriasis
- Moderate-to-severe plaque psoriasis
Her contribution in this field is centered on advanced therapeutic approaches for persistent inflammatory dermatoses.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.